-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Duocarmazine in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Duocarmazine in Epithelial Ovarian Cancer Drug Details: Trastuzumab duocarmazine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Duocarmazine in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Duocarmazine in Endometrial Cancer Drug Details: Trastuzumab duocarmazine (SYD-985) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Duocarmazine in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Duocarmazine in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Metastatic Breast Cancer Drug Details: DS-1062...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-4228 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-4228 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-4228 in Mantle Cell Lymphoma Drug Details: SYD-4228 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-4228 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-4228 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-4228 in Diffuse Large B-Cell Lymphoma Drug Details: SYD-4228 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-4228 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-4228 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-4228 in Follicular Lymphoma Drug Details: SYD-4228 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SYD-4228 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SYD-4228 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SYD-4228 in Marginal Zone B-cell Lymphoma Drug Details: SYD-4228 is...
-
Product Insights
Papillary Renal Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Papillary Renal Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Papillary Renal Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Papillary Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axitinib in Ductal Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axitinib in Ductal Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axitinib in Ductal Carcinoma Drug Details: Axitinib (Inlyta) is an anti-cancer agent....